450 related articles for article (PubMed ID: 18607857)
1. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
2. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.
Deconinck E; Miadi-Fargier H; Pen CL; Brice P
Pharmacoeconomics; 2010; 28(1):35-46. PubMed ID: 20014875
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
Blommestein HM; Issa DE; Pompen M; Ten Hoor G; Hogendoorn M; Joosten P; Zweegman S; Huijgens PC; Uyl-de Groot CA
Eur J Haematol; 2014; 92(5):398-406. PubMed ID: 24400940
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
[TBL] [Abstract][Full Text] [Related]
8. [Rituximab cost analysis for maintenance treatment of patients with follicular lymphoma].
Grupo de Farmacoeconomía del Linfoma Folicular
Farm Hosp; 2008; 32(1):25-34. PubMed ID: 18426699
[TBL] [Abstract][Full Text] [Related]
9. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
Lindgren P; Geborek P; Kobelt G
Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
[TBL] [Abstract][Full Text] [Related]
10. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.
Hayslip JW; Simpson KN
Clin Lymphoma Myeloma; 2008 Jun; 8(3):166-70. PubMed ID: 18650180
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of rituximab in follicular lymphoma.
Johnston KM; Bolbocean C; Connors J; Peacock S
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):569-77. PubMed ID: 23140274
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
14. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
van Agthoven M; Kramer MH; Sonneveld P; van der Hem KG; Huijgens PC; Wijermans PW; Kluin-Nelemans HC; Schaafsma MR; Biesma DH; Mattijssen V; Uyl-de Groot CA; Hagenbeek A
Haematologica; 2005 Oct; 90(10):1422-32. PubMed ID: 16219580
[TBL] [Abstract][Full Text] [Related]
16. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands.
Groot MT; Lugtenburg PJ; Hornberger J; Huijgens PC; Uyl-de Groot CA
Eur J Haematol; 2005 Mar; 74(3):194-202. PubMed ID: 15693788
[TBL] [Abstract][Full Text] [Related]
19. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
[TBL] [Abstract][Full Text] [Related]
20. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR
Value Health; 2015 Mar; 18(2):189-97. PubMed ID: 25773554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
